150 related articles for article (PubMed ID: 36921725)
1. Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumors.
Anthiya S; Öztürk SC; Yanik H; Tavukcuoglu E; Şahin A; Datta D; Charisse K; Álvarez DM; Loza MI; Calvo A; Sulheim E; Loevenich S; Klinkenberg G; Schmid R; Manoharan M; Esendağlı G; Alonso MJ
J Control Release; 2023 May; 357():67-83. PubMed ID: 36921725
[TBL] [Abstract][Full Text] [Related]
2. Nanoformulation of Apolipoprotein E3-Tagged Liposomal Nanoparticles for the co-Delivery of KRAS-siRNA and Gemcitabine for Pancreatic Cancer Treatment.
Wang F; Zhang Z
Pharm Res; 2020 Nov; 37(12):247. PubMed ID: 33216236
[TBL] [Abstract][Full Text] [Related]
3. Development of amino acid-modified biodegradable lipid nanoparticles for siRNA delivery.
Patel P; Fetse J; Lin CY; Guo Y; Hasan MR; Nakhjiri M; Zhao Z; Jain A; Cheng K
Acta Biomater; 2022 Dec; 154():374-384. PubMed ID: 36191773
[TBL] [Abstract][Full Text] [Related]
4. Human serum albumin-coated lipid nanoparticles for delivery of siRNA to breast cancer.
Piao L; Li H; Teng L; Yung BC; Sugimoto Y; Brueggemeier RW; Lee RJ
Nanomedicine; 2013 Jan; 9(1):122-9. PubMed ID: 22542825
[TBL] [Abstract][Full Text] [Related]
5. Targeted nanodelivery of siRNA against KRAS G12D inhibits pancreatic cancer.
Huang R; Du H; Cheng L; Zhang P; Meng F; Zhong Z
Acta Biomater; 2023 Sep; 168():529-539. PubMed ID: 37451658
[TBL] [Abstract][Full Text] [Related]
6. K-ras oncogene silencing strategy reduces tumor growth and enhances gemcitabine chemotherapy efficacy for pancreatic cancer treatment.
Réjiba S; Wack S; Aprahamian M; Hajri A
Cancer Sci; 2007 Jul; 98(7):1128-36. PubMed ID: 17489984
[TBL] [Abstract][Full Text] [Related]
7. Targeting KRAS Mutant Lung Cancer Cells with siRNA-Loaded Bovine Serum Albumin Nanoparticles.
Mehta A; Dalle Vedove E; Isert L; Merkel OM
Pharm Res; 2019 Jul; 36(9):133. PubMed ID: 31289919
[TBL] [Abstract][Full Text] [Related]
8. Combination of siRNA-directed Kras oncogene silencing and arsenic-induced apoptosis using a nanomedicine strategy for the effective treatment of pancreatic cancer.
Zeng L; Li J; Wang Y; Qian C; Chen Y; Zhang Q; Wu W; Lin Z; Liang J; Shuai X; Huang K
Nanomedicine; 2014 Feb; 10(2):463-72. PubMed ID: 24028894
[TBL] [Abstract][Full Text] [Related]
9. Electrostatic adsorption of polyanions onto lipid nanoparticles controls uptake, trafficking, and transfection of RNA and DNA therapies.
Nabar N; Dacoba TG; Covarrubias G; Romero-Cruz D; Hammond PT
Proc Natl Acad Sci U S A; 2024 Mar; 121(11):e2307809121. PubMed ID: 38437543
[TBL] [Abstract][Full Text] [Related]
10. Lipid nanoparticles to silence androgen receptor variants for prostate cancer therapy.
Quick J; Santos ND; Cheng MHY; Chander N; Brimacombe CA; Kulkarni J; van der Meel R; Tam YYC; Witzigmann D; Cullis PR
J Control Release; 2022 Sep; 349():174-183. PubMed ID: 35780952
[TBL] [Abstract][Full Text] [Related]
11. Sequential Targeting TGF-β Signaling and KRAS Mutation Increases Therapeutic Efficacy in Pancreatic Cancer.
Pei Y; Chen L; Huang Y; Wang J; Feng J; Xu M; Chen Y; Song Q; Jiang G; Gu X; Zhang Q; Gao X; Chen J
Small; 2019 Jun; 15(24):e1900631. PubMed ID: 31033217
[TBL] [Abstract][Full Text] [Related]
12. Mutant KRAS is a druggable target for pancreatic cancer.
Zorde Khvalevsky E; Gabai R; Rachmut IH; Horwitz E; Brunschwig Z; Orbach A; Shemi A; Golan T; Domb AJ; Yavin E; Giladi H; Rivkin L; Simerzin A; Eliakim R; Khalaileh A; Hubert A; Lahav M; Kopelman Y; Goldin E; Dancour A; Hants Y; Arbel-Alon S; Abramovitch R; Shemi A; Galun E
Proc Natl Acad Sci U S A; 2013 Dec; 110(51):20723-8. PubMed ID: 24297898
[TBL] [Abstract][Full Text] [Related]
13. Development of siRNA payloads to target KRAS-mutant cancer.
Yuan TL; Fellmann C; Lee CS; Ritchie CD; Thapar V; Lee LC; Hsu DJ; Grace D; Carver JO; Zuber J; Luo J; McCormick F; Lowe SW
Cancer Discov; 2014 Oct; 4(10):1182-1197. PubMed ID: 25100204
[TBL] [Abstract][Full Text] [Related]
14. In vivo activation of PEGylated long circulating lipid nanoparticle to achieve efficient siRNA delivery and target gene knock down in solid tumors.
Sasayama Y; Hasegawa M; Taguchi E; Kubota K; Kuboyama T; Naoi T; Yabuuchi H; Shimai N; Asano M; Tokunaga A; Ishii T; Enokizono J
J Control Release; 2019 Oct; 311-312():245-256. PubMed ID: 31505222
[TBL] [Abstract][Full Text] [Related]
15. Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer.
Bäumer S; Bäumer N; Appel N; Terheyden L; Fremerey J; Schelhaas S; Wardelmann E; Buchholz F; Berdel WE; Müller-Tidow C
Clin Cancer Res; 2015 Mar; 21(6):1383-94. PubMed ID: 25589625
[TBL] [Abstract][Full Text] [Related]
16. Development of Lipidoid Nanoparticles for siRNA Delivery to Neural Cells.
Khare P; Dave KM; Kamte YS; Manoharan MA; O'Donnell LA; Manickam DS
AAPS J; 2021 Dec; 24(1):8. PubMed ID: 34873640
[TBL] [Abstract][Full Text] [Related]
17. A robust post-insertion method for the preparation of targeted siRNA LNPs.
Swart LE; Koekman CA; Seinen CW; Issa H; Rasouli M; Schiffelers RM; Heidenreich O
Int J Pharm; 2022 May; 620():121741. PubMed ID: 35421533
[TBL] [Abstract][Full Text] [Related]
18. Production of siRNA-Loaded Lipid Nanoparticles using a Microfluidic Device.
Maeki M; Okada Y; Uno S; Niwa A; Ishida A; Tani H; Tokeshi M
J Vis Exp; 2022 Mar; (181):. PubMed ID: 35404350
[TBL] [Abstract][Full Text] [Related]
19. Modular Lipid Nanoparticle Platform Technology for siRNA and Lipophilic Prodrug Delivery.
van der Meel R; Chen S; Zaifman J; Kulkarni JA; Zhang XRS; Tam YK; Bally MB; Schiffelers RM; Ciufolini MA; Cullis PR; Tam YYC
Small; 2021 Sep; 17(37):e2103025. PubMed ID: 34337865
[TBL] [Abstract][Full Text] [Related]
20. Efficient siRNA Delivery by Lipid Nanoparticles Modified with a Nonstandard Macrocyclic Peptide for EpCAM-Targeting.
Sakurai Y; Mizumura W; Murata M; Hada T; Yamamoto S; Ito K; Iwasaki K; Katoh T; Goto Y; Takagi A; Kohara M; Suga H; Harashima H
Mol Pharm; 2017 Oct; 14(10):3290-3298. PubMed ID: 28789523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
